Author

Diego Moreno Baca

Institution: Novo Nordisk Canada (Canada)

Observed institution: Novo Nordisk Canada (Canada)

ORCID: 0000-0002-4128-0622

Observed ORCID: 0000-0002-4128-0622

OpenAlex ID: A5118994408

Real-world quality of life and healthcare resource utilization in patients with metabolic dysfunction-associated steatohepatitis

2026 · Jens Marquardt, Riku Ota, et al. · JHEP Reports · 2

Cardiometabolic comorbidity and health outcomes of persons with metabolic dysfunction–associated steatotic liver disease (MASLD) in Ontario, Canada

2026 · Keyur Patel, Diego Moreno Baca, et al. · Canadian Liver Journal · 1

Health care resource utilization and cost of metabolic dysfunction–associated steatotic liver disease (MASLD) in Ontario, Canada: An observational study

2026 · Keyur Patel, Diego Moreno Baca, et al. · Canadian Liver Journal

Reply to “Real-world quality of life and healthcare resource utilization in patients with metabolic dysfunction-associated steatohepatitis – Circular definition of CVRM comorbidities undermines the validity of core subgroup comparisons”

2026 · Jens Marquardt, Riku Ota, et al. · JHEP Reports

EE342 Healthcare Utilization and Cost of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Ontario, Canada: An Observational Study

2025 · Keyur Patel, Diego Moreno Baca, et al. · Value in Health

Works count: 5

Citation count: 3

H-index: 1

I10-index: